TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00984152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
Description: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC + Efavirenz (Atripla) Once-Daily
Description: TDF/FTC + Efavirenz (Atripla) Once-Daily
Study: NCT00930501

Intervention type: BIOLOGICAL
Intervention: blood tests
Description: time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
Study: NCT05346380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus VE2 NIR Imaging System
Description: A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus VE2 NIR Imaging System
Description: A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
Study: NCT04379635

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: administered via IV infusion
Study: NCT02629887

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-inflatable supraglottic airway
Description: at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face Mask
Description: at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-Piece Resuscitator
Description: T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-Piece Resuscitator
Description: T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
Study: NCT00170846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin Inhibitors (CNI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin Inhibitors (CNI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate acid (MPA)/Azathioprine (AZA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate acid (MPA)/Azathioprine (AZA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate acid (MPA)/Azathioprine (AZA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Study: NCT04379635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: administered via IV infusion
Study: NCT00170846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Study: NCT00224120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: 8 mg daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for 12 weeks
Study: NCT04808726

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teach Back Method
Description: Effect of Breastfeeding Training on Breastfeeding Success Using The Teach Back Method: Randomized Controlled Study
Study: NCT04644146

Intervention type: GENETIC
Intervention: GENETIC
Description: It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing

Intervention type: GENETIC
Intervention: GENETIC
Description: It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
Study: NCT00438360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A microemulsion
Description: Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
Study: NCT03072394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic
Description: Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
Study: NCT00967694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: Nitrous oxide sedation by inhalation
Study: NCT02303756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillcam® COLON Capsule
Description: colonoscopy
Study: NCT01334216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHICA Smoking Cessation Module
Description: The CHICA module helped to screen parents for smoking and assist them in quitting.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CHICA Placebo
Description: This was CHICA without the study module.
Study: NCT04333888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: fMRI neurofeedback training of amygdala downregulation
Study: NCT00140907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: 25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: 25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
Study: NCT01032434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: sertraline: 50-200mg/day
Study: NCT03645096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 500 mg
Description: Pregnenolone 500 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 500 mg
Description: Pregnenolone 500 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 500 mg
Description: Pregnenolone 500 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 500 mg
Description: Pregnenolone 500 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 500 mg
Description: Pregnenolone 500 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 500 mg
Description: Pregnenolone 500 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 800 mg
Description: Pregnenolone 800 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 800 mg
Description: Pregnenolone 800 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 800 mg
Description: Pregnenolone 800 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 800 mg
Description: Pregnenolone 800 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 800 mg
Description: Pregnenolone 800 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 800 mg
Description: Pregnenolone 800 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule manufactured to mimic pregnenolone capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule manufactured to mimic pregnenolone capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule manufactured to mimic pregnenolone capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule manufactured to mimic pregnenolone capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule manufactured to mimic pregnenolone capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule manufactured to mimic pregnenolone capsule.
Study: NCT03588806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xtampza ER (oxycodone)
Description: Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
Study: NCT00123162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single vaginal dose of placebo and monitored for 4 hours.
Study: NCT03089333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide 5Mg Tablet
Description: Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide 5Mg Tablet
Description: Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
Study: NCT04453358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InCourage-Connect
Description: This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InCourage
Description: This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
Study: NCT00833963

Intervention type: DRUG
Intervention: Trastuzumab
Description: Participants will receive trastuzumab as determined by their treating physicians' standards of care.

Intervention type: DRUG
Intervention: Trastuzumab
Description: Participants will receive trastuzumab as determined by their treating physicians' standards of care.

Intervention type: DRUG
Intervention: Pertuzumab
Description: Participants will receive pertuzumab as determined by their treating physicians' standards of care.

Intervention type: DRUG
Intervention: Ado-Trastuzumab Emtansine
Description: Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
Study: NCT02767869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banaba
Description: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
Study: NCT03125031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow adhesive adult/pediatric sensor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow adhesive adult/neonatal sensor
Study: NCT00475241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure therapy for PTSD
Description: exposure-based treatment for PTSD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present centered therapy for PTSD
Description: present focused coping and problem solving for PTSD
Study: NCT00309166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix vaccine
Description: All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
Study: NCT01191801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vosaroxin + cytarabine
Description: Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + cytarabine
Description: Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)
Study: NCT01380275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Description: This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
Study: NCT00309166

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B vaccine
Description: All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
Study: NCT00723983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan succinate
Description: Sumatriptan succinate 50 mg taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan succinate
Description: Sumatriptan succinate 50 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 Study Patch
Description: NP101 study patch 4 hour application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 Study Patch
Description: NP101 study patch 4 hour application
Study: NCT02034214

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life skills education
Description: The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life skills education
Description: The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reproductive health services
Description: All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reproductive health services
Description: All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic livelihoods
Description: The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
Study: NCT01484197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 µg indacaterol maleate (LB)
Description: 75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
Study: NCT02983851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation
Description: Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive mechanical ventilation
Description: Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
Study: NCT01665040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation device implantation
Description: Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan.
Study: NCT01484197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 µg indacaterol maleate (PoS)
Description: 75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 37.5 µg indacaterol maleate (PoS)
Description: 37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol (LB)
Description: Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol (LB)
Description: Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
Study: NCT00089024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy.
Study: NCT03230006

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: The UP will be conducted in a standardized fashion, over 16 sessions, following the published therapist guide with minor refinements for application in the proposed comorbid population.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Take Control
Description: TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
Study: NCT02859844

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Tibial Nerve Stimulation (TTNS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation (TTNS)